View More
Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of CME/CE/CPE-certified ClinicalThought™ commentaries!
How do biosimilars compare with reference biologics and small-molecule compounds? Here’s my take.
Rowena N. Schwartz, PharmD, BCOP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.2 Nursing contact hours
Pharmacists:
0.25 contact hours (0.03 CEUs)
Released: November 14, 2018
Expiration: November 13, 2019
Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112
Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.